Digest Network Come funziona
Network
/
Società
En
Non verificato

Enanta Pharmaceuticals, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaHIV, AIDS e malattie autoimmuniMedicina - VarieSalute

33 comunicati stampa

Guarda tutti i comunicati
17/11/2025
Mercato azionario
Salute
HIV, AIDS e malattie autoimmuni
Biotecnologia
Medicina - Varie
Farmaceutica
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2025
Fonte
Enanta Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
04/11/2025
Eventi
Web e Social Network
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Enanta Pharmaceuticals to Participate in Upcoming Investor Conferences
Fonte
Enanta Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
20/10/2025
Salute
HIV, AIDS e malattie autoimmuni
Biotecnologia
Sanità
Medicina - Varie
Farmaceutica
Eventi
Enanta Pharmaceuticals Presents New Data for Zelicapavir, its N-Protein Inhibitor, and EDP-323, its L-Protein Inhibitor, Both in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025
Fonte
Enanta Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
07/10/2025
Scienza
Biotecnologia
Farmaceutica
Salute
HIV, AIDS e malattie autoimmuni
Sanità
Eventi
Industria
Enanta Pharmaceuticals to Present Data for Zelicapavir and EDP-323, Two Candidates in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025
Fonte
Enanta Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
02/10/2025
Scienza
Biotecnologia
Farmaceutica
Finanza
Salute
Associazioni/Professionisti
Medicina - Varie
Enanta Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Fonte
Enanta Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
01/10/2025
Scienza
Biotecnologia
Farmaceutica
Finanza
Salute
Associazioni/Professionisti
Medicina - Varie
Enanta Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
Fonte
Enanta Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
30/09/2025
Associazioni/Professionisti
Salute
HIV, AIDS e malattie autoimmuni
Biotecnologia
Finanza
Farmaceutica
Enanta Pharmaceuticals Announces Proposed Public Offering of Common Stock
Fonte
Enanta Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
29/09/2025
Salute
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Web e Social Network
Telefonia e Varie
Industria
Enanta Pharmaceuticals Reports Positive Topline Results from its Phase 2b Study of Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults
Fonte
Enanta Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
26/09/2025
Web e Social Network
Telefonia e Varie
Industria
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Enanta Pharmaceuticals to Present Topline Results from its Phase 2b Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults
Fonte
Enanta Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
03/09/2025
Salute
HIV, AIDS e malattie autoimmuni
Scienza
Farmaceutica
Mercato del lavoro
Enanta Pharmaceuticals Announces the Passing of its Beloved and Respected Longtime Chief Financial and Administrative Officer Paul J. Mellett Jr.
Fonte
Enanta Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0